COVID and Aspirin
-
https://www.timesofisrael.com/aspirin-may-protect-against-covid-19-israeli-research-finds/
In the peer-reviewed research, they found that in a sample of Israeli PCR tests, patients who take small doses of aspirin were 29 percent less likely to test positive. They cross-referenced 10,477 results with medical records covering what preventive drugs patients take.
“We were really excited to see a big reduction in the proportion of people testing positive, and this gives a promising indication that aspirin, such a well-known and inexpensive drug, may be helpful in fighting the pandemic,” Milana Frenkel-Morgenstern of Bar-Ilan University told The Times of Israel.
Get The Start-Up Israel's Daily Start-Up by email and never miss our top stories Free Sign Up
As well as concluding that people who take aspirin, which was developed more than 120 years ago, are less likely to be diagnosed with the virus, Frenkel-Morgenstern hit on another “important” finding: Aspirin users who are diagnosed with COVID-19 are likely to have a shorter illness — by about two days — and be less likely to suffer from aftereffects of the coronavirus, she reported.
“This finding with regard to ‘long COVID,’ a phenomenon that is a real concern, is very important,” said Frenkel-Morgenstern, whose past research has been ahead of the curve. Her study in June, in which she concluded that vitamin D gave people a major boost in fighting COVID-19, was followed by similar claims from many other researchers.
The aspirin study focused on people who take “baby” 75 milligram doses of the drug for primary prevention of cardiovascular diseases, but don’t already have such diseases. Results were adjusted to account for age and co-morbidities.
Abstract here: https://febs.onlinelibrary.wiley.com/doi/10.1111/febs.15784
Acetylsalicylic acid (aspirin) is commonly used for primary and secondary prevention of cardiovascular diseases. Aspirin use is associated with better outcomes among COVID‐19 positive patients. We hypothesized that aspirin use for primary cardiovascular disease prevention might have a protective effect on COVID‐19 susceptibility and disease duration. We conducted a retrospective population‐based cross‐sectional study, utilizing data from the Leumit Health Services database. The proportion of patients treated with aspirin was significantly lower among the COVID‐19‐positive group, as compared to the COVID‐19‐negative group (73 (11.03 %) vs. 1548 (15.77%); p=0.001). Aspirin use was associated with lower likelihood of COVID‐19 infection, as compared to non‐users (adjusted OR 0.71 (95% CI, 0.52 to 0.99; p=0.041). Aspirin users were older (68.06 ± 12.79 vs. 56.63 ± 12.28 years of age; p<0.001), presented a lower BMI (28.77±5.4 vs. 30.37±4.55; p<0.0189) and showed higher prevalence of hypertension (56, 76.71%), diabetes (47, 64.38%) and COPD (11, 15.07%) than showed the aspirin non‐users (151, 25.64%, p<0.001; 130, 22.07%, p<0.001; and 43, 7.3%, p=0.023, respectively). Moreover, COVID‐19 disease duration (considered as the time between the first positive and second negative COVID‐19 RT‐PCR test results) among aspirin users was significantly shorter, as compared to aspirin non‐users (19.8±7.8 vs. 21.9± 7.9 p= 0.045). Among hospitalized COVID‐positive patients, a higher proportion of surviving subjects were treated with aspirin (20, 19.05%), as opposed to 1 dead subject (14.29%), although this difference was not significant (p=0.449). In conclusion, we observed inverse association between the likelihood of COVID‐19 infection, disease duration and mortality and aspirin use for primary prevention.
-
Inhaled Steroids: https://nodebb.the-new-coffee-room.club/topic/7492/another-covid-therapy?_=1615555430984
Systemic Steroids: https://nodebb.the-new-coffee-room.club/topic/1873/major-covid-treatment-breakthrough-dexamethasone?_=1615555430987
And now, aspirin.
All have anti-inflammatory effects.
